Navigation Links
Epizyme, Inc. Reports Second Quarter 2013 Financial Results
Date:7/31/2013

s of $88.7 million.
  • Continued Progress with EPZ-5676 Development Epizyme is enrolling patients in the dose escalation stage of its Phase 1 study of EPZ-5676 and has added four clinical sites in 2013 for a total of five active sites at this time. The Company expects to initiate an expansion cohort later in the year, limited to patients with MLL-r, in as many as twelve sites in both the United States and Europe. In June, Epizyme scientists published pre-clinical data on EPZ-5676 in the journal Blood, showing the correlation between DOT1L inhibition and anti-proliferative effects specific to MLL-r leukemias, including tumor growth inhibition and durable anti-tumor effects in animal models that were sustained after dosing had been completed. 
  • Companion Diagnostic Collaboration for EPZ-5676 In April, Epizyme announced a collaboration with Abbott Molecular Inc. to develop a molecular companion diagnostic to identify eligible patients for EPZ-5676.
  • Initiation of Phase 1/2 Clinical Trial for EPZ-6438 In June, Epizyme announced the enrollment of its first patient in a Phase 1/2 study of EPZ-6438 (referred to as E7438 by Eisai). Epizyme plans to initiate the Phase 2 portion of this study in 2014.
  • Intellectual Property In April, the Company was granted the first patent covering the composition of matter of EPZ-6438. This patent expires in 2032. In addition, in April, the US Patent and Trademark Office issued a Notice of Allowance for a patent application titled "Diagnostic and Therapeutic Targets for Leukemia" with claims directed to methods of identifying DOT1L inhibitor compounds for the treatment of leukemia. The patent to be issued from this application carries a patent term to at least 2030.
  • Pipeline Development Epizyme continues to conduct preclinical studies to identify additional genetically defined cancers for potential treatment with its therapeutic candi
    '/>"/>

  • SOURCE Epizyme, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. China Medical Flat Panel Detector Market & Pressure Injector 2013 Research Reports Now Available at ReportsnReports.com
    2. Global Pain Management Therapeutics Market to 2019 - Impact of Patent Expiries Offset by Demand for Neuropathic and Rheumatoid Pain Medications and Strong Pipeline: MarketResearchReports.Biz
    3. Arena Pharma, Geron, Incyte, and Spectrum Pharma Under AAAResearchReports.com Microscope
    4. China Radiotherapy Simulator Market & Digital Radiography 2013 Research Reports Now Available at ReportsnReports.com
    5. Neurocrine Biosciences Reports Second Quarter 2013 Results
    6. United Therapeutics Corporation Reports Second Quarter 2013 Financial Results
    7. Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2013
    8. Global Activated Carbon Market 2012-2016: Latest Market Share, Growth, Analysis, Size, Trends & Forecast Research Report 2012-2016 Available at Marketresearchreports.biz
    9. Cepheid Reports 2013 Second Quarter Results
    10. Quest Diagnostics Reports Second Quarter 2013 Financial Results
    11. Global GIS Market in the Retail Industry to 2016: Industry Analysis, Growth, Strategy, Size, Shares, Trend and Forecast Research Report Available at MarketResearchReports
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/30/2014)... Fla. , July 30, 2014  Dyadic ... biotechnology company whose patented and proprietary technologies are ... and other proteins for the bioenergy, bio-based chemical, ... appointment of Thomas "Tom" Dubinski as Vice President ... for leading the financial and information technology operations ...
    (Date:7/30/2014)... 30, 2014 NCERC at Southern ... present his findings on corn stover pretreatment methods ... week in Washington, D.C. , “Arun’s selection ... is a testament to the success of our ... “Thanks to the foresight and vision of SIUE ...
    (Date:7/30/2014)... LayerBio, Inc., an MIT spinoff developing novel drug ... seed financing from friends and family investors. Proceeds from ... novel sustained-release product for ophthalmology. , "We are grateful ... to this important work," said Dr. Ken Mandell, Founder ... areas in which innovations in drug delivery have already ...
    (Date:7/29/2014)... --  Sequenom, Inc. (NASDAQ: SQNM ), ... solutions, and Mayo Medical Laboratories (MML), the ... the United States , have announced a license ... "We have great appreciation for Mayo Clinic,s commitment ... the opportunity to partner with the organization,s leading clinical ...
    Breaking Biology Technology:Thomas Dubinski joins Dyadic as Chief Financial Officer 2Thomas Dubinski joins Dyadic as Chief Financial Officer 3Thomas Dubinski joins Dyadic as Chief Financial Officer 4NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 2NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 3Sequenom Enters Into License Agreement With Mayo Medical Laboratories 2Sequenom Enters Into License Agreement With Mayo Medical Laboratories 3Sequenom Enters Into License Agreement With Mayo Medical Laboratories 4
    ... Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: NTII ... million from Merz Pharmaceuticals GmbH (Merz) for ... Memantine for the treatment of,moderate-to-severe Alzheimer,s disease ... an exclusive marketing agreement, NTI currently receives,quarterly ...
    ... CITY, April 30 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.,(NASDAQ: ... company focused on,endocrine therapy and oncology, today announced ... CEO of Andros Men,s Health Institutes,in The Netherlands, ... a Poster,Session at the 23rd Annual European Association ...
    ... ... First Non-GAAP Profit; Sales Guidance Revised Upward, ... Neurology and Cancer, First Quarter 2008 Financial Highlights:, - Soliris(R) (eculizumab) net product sales were ... Q4 2007., - Q1 GAAP net loss was $4.2 million, or $0.11 net loss per share, ...
    Cached Biology Technology:AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan 2AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan 3AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan 4AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan 5AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan 6Alexion Reports First Quarter 2008 Results 2Alexion Reports First Quarter 2008 Results 3Alexion Reports First Quarter 2008 Results 4Alexion Reports First Quarter 2008 Results 5Alexion Reports First Quarter 2008 Results 6Alexion Reports First Quarter 2008 Results 7Alexion Reports First Quarter 2008 Results 8Alexion Reports First Quarter 2008 Results 9Alexion Reports First Quarter 2008 Results 10Alexion Reports First Quarter 2008 Results 11Alexion Reports First Quarter 2008 Results 12
    (Date:7/30/2014)... journal Scientific Reports , published by Nature ... that while global temperature is indeed increasing, so too ... each year,s average hottest and coldest temperatures will likely ... a wider range of potential high and low temperate ... even as overall temperatures rise, we may still continue ...
    (Date:7/29/2014)... methods and applications for imaging and manipulation of the ... were the inspiration behind Neurophotonics , a new ... optics and photonics. , The first issue coincides with ... States, and a special section features articles that lay ... impact that optics and photonics will have on advancing ...
    (Date:7/29/2014)... In the high-tech world of science, researchers sometimes ... Barbara,s Douglas McCauley did just that to study ... muricatum ) on coral reef ecosystems at two ... Using direct observation, animal tracking and computer simulation, ... Ecology, Evolution and Marine Biology, and his colleagues ...
    Breaking Biology News(10 mins):Big data confirms climate extremes are here to stay 2SPIE launches Neurophotonics journal with special section on BRAIN Initiative 2SPIE launches Neurophotonics journal with special section on BRAIN Initiative 3Underwater elephants 2Underwater elephants 3
    ... 2013)In a series of papers to be presented next ... mechanism operating in the roots of a tropical grass ... greenhouse gas emissions. Referred to as "biological nitrification ... of nitrogen applied to soil as fertilizer into nitrous ...
    ... This news release is available in German ... daughter; like father, like son. Evolutionary biologists at the universities in ... also applies to inheriting a long life at least for ... descendants of these insects mostly inherit their lifespan from their own ...
    ... disease indicate future joint problems? Although researchers and clinicians ... chronic inflammatory diseases - periodontal disease and rheumatoid arthritis ... In an article published today in PLOS Pathogens ... and Systemic Diseases group researcher Jan Potempa, PhD, DSc, ...
    Cached Biology News:'Grassroots action' in livestock feeding to help curb global climate change 2'Grassroots action' in livestock feeding to help curb global climate change 3'Grassroots action' in livestock feeding to help curb global climate change 4Inheritance of lifespan is sex-dependent in fruit flies 2Bacteria responsible for gum disease facilitates rheumatoid arthritis 2
    Anti-Chicken IgY, (IgG) F(ab')2 Fragment Specific....
    Presenilin 2 Immunogen: Synthetic peptide corresponding to residues 31-47 of human Presenilin 2. Storage: -20 C, Avoid Freeze/Thaw Cycles...
    SHP-2 Antibody...
    200 μg per ml DNA in 10 SSPE, 2 Denhardt's...
    Biology Products: